Reserved capacity agreements for biologics CDMOs Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines reserved capacity agreements for biologics CDMOs, where biopharma companies book manufacturing capacity at a contract manufacturer ahead of need, through take-or-pay terms, dedicated suites or shared multi-product capacity. It tests how far reserved and shared capacity becomes the standard way to secure biologics supply by 2034, and what that means for biopharma companies and manufacturers.

Order books are large. Samsung Biologics reported on 21 October 2026 that its cumulative contract orders exceed USD 21.9 billion, and it raised its 2026 revenue growth guidance to 20% from a range of 15% to 20%, with global capacity of 845,000 liters. The conclusion is that customers have committed many years of future volume, and a manufacturer with a large order book can plan new capacity with confidence.

Capacity is moving to the United States. Samsung Biologics acquired a 60,000 liter site in Rockville, Maryland from GSK in March 2026, its first US biomanufacturing site, while Lonza Group AG holds 484,000 liters of US mammalian capacity and nearly two thirds of its capacity lies in the United States, including 332,000 liters at Vacaville, California, which it bought from Roche for USD 1.2 billion in 2024. The conclusion is that biopharma customers want supply close to the US market, and sites already built carry a clear advantage over new construction.

Dedicated partnerships are growing. Fujifilm and Johnson & Johnson announced a 10 year partnership worth USD 2 billion in late 2025, with a dedicated facility of more than 160,000 square feet at Holly Springs, North Carolina, and Resilience is adding a USD 750 million expansion in Cincinnati with Eli Lilly and Company, announced in July 2026. The conclusion is that large customers now pay for dedicated facilities with long contracts, which gives the manufacturer steady revenue and the customer secure supply.

Policy is shaping where capacity sits. On 9 October 2025 the US Senate advanced its fiscal 2026 defense bill with BIOSECURE language that would bar federal agencies and their contractors from using services of designated biotechnology companies of concern. The conclusion is that customers weigh the home country of a manufacturer when they reserve capacity, and suppliers in the United States and allied countries gain from this.

The brief treats reserved capacity agreements for biologics CDMOs as an accelerating signal with an eight year horizon to 2034. It identifies which manufacturers, customers and regions move first and what each means for price, utilisation and supply security. It is a focused 110-page decision brief that presents an indicative trajectory rather than a segmented market model.

Large-scale mammalian capacity is the core asset. Samsung Biologics added 180,000 liters with Plant 5 in 2025, and plans three more plants at Bio Campus II for 2032 with 720,000 liters of total capacity, while Lonza holds 219,000 liters in Europe and 90,000 liters in Singapore. The conclusion is that a small number of manufacturers hold most of the world supply of large bioreactors, and customers must book early to secure it.

Specialty modalities widen the offer. Samsung Biologics entered the antibody drug conjugate CDMO market in 2025 with a facility at Songdo and plans a drug product launch in 2027. The conclusion is that manufacturers add new modalities to hold existing customers and win new ones, and reserved agreements now cover more than antibodies.

Fill-finish capacity is being built alongside. Vetter began work on a clinical fill-finish site in Des Plaines, Illinois at a cost of about EUR 250 million, with groundbreaking in June 2025 and readiness expected by the end of 2029, and GRAM announced a USD 100 million line in Michigan in April 2026 with capacity for 50 million units a year. The conclusion is that drug product capacity is being added in the United States at the same time as drug substance capacity, which supports full supply chains close to the market.

Customers read capacity as a strategic asset. Lonza stated at its 2026 Capital Markets Day that it is not in a capacity race with other companies, while Samsung Biologics describes its approach as strategically expanding capacity. The conclusion is that manufacturers choose between filling reserved capacity before building and building ahead of demand, and the choice depends on the strength of the order book.

The limits are over-capacity and utilisation risk, geopolitical limits on China-linked suppliers, and limits in demand forecasting. The brief tests each limit against the contract and capacity evidence to 2034.

The reserved capacity agreements for biologics CDMOs market, covering revenue earned by biologics contract development and manufacturing organisations under reserved capacity, take-or-pay, dedicated suite and shared capacity agreements for drug substance and drug product manufacturing, measured by annual CDMO revenue under such agreements, and excluding small molecule and peptide manufacturing, cell and gene therapy manufacturing, single batch spot orders and in-house biopharma manufacturing, is valued at USD 10–15 billion in 2026 and is projected to reach USD 23.05–34.57 billion by 2034, at a CAGR of 11%.

The 2026 base rests on revenue from reserved, dedicated and shared capacity agreements held by Lonza Group AG, Samsung Biologics Co., Ltd., Fujifilm Holdings Corporation, WuXi Biologics (Cayman) Inc., Thermo Fisher Scientific Inc. and other biologics manufacturers. Growth then follows the amount of capacity under contract, the share of revenue under reserved agreements and the entry of regional shared networks.

The forecast is sensitive to utilisation of newly built plants, the pace of onshoring policy and the share of customer volume that moves to dedicated facilities.

The base case assumes steady growth in capacity under contract and in reserved revenue, bringing the inflection to about 2029 and a 2034 value near the middle of the range. An accelerated case assumes fast growth in antibody, obesity and ADC pipelines and strong onshoring policy, bringing the inflection to 2028 and lifting the 2034 value to the top of the range. A delayed case assumes over-capacity at new plants and weaker demand growth, moving the inflection to 2031 and holding growth at the bottom of the range.

Growth drivers

• Biopharma demand for secure large-scale capacity.
• CDMO need for committed volumes.
• Onshoring and supply security policy.
• Growth of antibody, obesity and ADC drug pipelines.

Enablers

• Process and scheduling tools.
• Customer and CDMO contracts.
• Contract and project evidence.
• Biopharma and CDMO site partnerships.

Restraints and barriers

• Price pressure and return on investment.
• Over-capacity and utilisation risk.
• Geopolitical limits on China-linked suppliers.
• Differences in national supply and trade rules.

The direction of reserved capacity agreements for biologics CDMOs is set by biopharma demand for secure large-scale capacity, CDMO need for committed volumes, onshoring and supply security policy, process and scheduling tools, and the readiness of customers and manufacturers to commit to long contracts.

The key participants in reserved capacity agreements for biologics CDMOs and CDMO capacity include Lonza Group AG, Samsung Biologics Co., Ltd., Fujifilm Holdings Corporation, Thermo Fisher Scientific Inc., WuXi Biologics (Cayman) Inc., Novo Holdings A/S, National Resilience, Inc., Cambrex Corporation, Siegfried Holding AG, Vetter Pharma-Fertigung GmbH & Co. KG, AGC Inc., Boehringer Ingelheim International GmbH, Celltrion, Inc., Lotte Corporation, SK Inc., Merck KGaA, Evonik Industries AG, Eli Lilly and Company, Johnson & Johnson, Bristol-Myers Squibb Company, Laboratorios Farmaceuticos Rovi, S.A., Bachem Holding AG, PolyPeptide Group AG, Sartorius AG, Danaher Corporation, Repligen Corporation, Pfizer Inc., Novartis AG, Roche Holding Ltd, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Inc., Gilead Sciences, Inc., AbbVie Inc., Sanofi, GSK plc, Merck & Co., Inc., Novo Nordisk A/S, the US Food and Drug Administration, the European Medicines Agency, the US Department of Commerce and the Drug, Chemical and Associated Technologies Association.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as shared and regional capacity reaches scale.

Lonza Group AG, Samsung Biologics Co., Ltd. and Fujifilm Holdings Corporation lead among large biologics CDMOs, National Resilience, Inc., Cambrex Corporation and Vetter Pharma-Fertigung GmbH & Co. KG lead among specialty and regional providers, and Eli Lilly and Company and Johnson & Johnson lead among customers that fund dedicated capacity. Competitive intensity is rising as new US sites open and customers weigh the home country of a supplier.

Where value migrates.

In 2026 value sits with large biologics CDMOs that hold ready large-scale capacity and long order books. By 2029 it moves toward manufacturers with regional capacity in several markets and flexible shared networks, because customers want supply close to each market and cover for demand swings. By 2034 it settles with reserved and shared capacity as the standard way to secure supply, where scale, scheduling skill and long customer contracts carry the margin. Margins hold for manufacturers with high utilisation and long contracts, and narrow for those that build ahead of demand without committed customers.

Large order books, onshoring investment and dedicated customer partnerships support growth, while over-capacity risk, geopolitical limits and demand forecasting limits hold back the pace.

Weak utilisation at new plants, changes in trade policy or slower pipeline growth could slow progress. The brief therefore tracks four indicators: contract value and booked capacity, capacity under contract, the share of revenue under reserved agreements and utilisation of new plants.

Reserved large-scale capacity first, then shared and regional capacity at scale, then standard status for reserved and shared capacity is the expected order of change.